Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multi-Center, Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of YK012 in Participants With B-cell Acute Lymphoblastic Leukemia

NCT06580301 is registered in ClinicalTrials.gov with Excyte Biopharma Ltd as lead sponsor.

NCT NCT06580301
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06580301 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multi-Center, Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of YK012 in Participants With B-cell Acute Lymphoblastic Leukemia
Lead sponsor
Excyte Biopharma Ltd
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 25, 2024
Completion date
June 30, 2027
Enrollment
46 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell acute lymphoblastic leukemia